这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

Sarilumab (anti-IL-6Rα)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR)
  • 反应种属: Cynomolgus,Human
  • 亚型: Human IgG1
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
S412003-1mg
1mg 期货 Stock Image
S412003-5mg
5mg 期货 Stock Image
S412003-10mg
10mg 期货 Stock Image

基本信息

产品名称 Sarilumab (anti-IL-6Rα)
别名 Sarilumab; SAR153191; REGN88; 西鲁库单抗; CD 126 antibody; CD126 antibody; CD126 antigen antibody; gp80 antibody; IL 6R 1 antibody; IL 6R alpha antibody; IL 6R antibody; IL-6 receptor alpha chain antibody; IL-6 receptor subunit alpha antibody; IL-6R 1 antibody
英文别名 Sarilumab; SAR153191; REGN88; CD 126 antibody; CD126 antibody; CD126 antigen antibody; gp80 antibody; IL 6R 1 antibody; IL 6R alpha antibody; IL 6R antibody; IL-6 receptor alpha chain antibody; IL-6 receptor subunit alpha antibody; IL-6R 1 antibody; IL-6R
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 IL6R
应用 Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR)
反应种属 Cynomolgus,Human
偶联标记 Unconjugated

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG1
轻链亚型 Kappa
SDS-PAGE 27.0 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 186.5 kDa, under non-reducing conditions.
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 1189541-98-7

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Strand V, Reaney M, Chen CI, Proudfoot CW, Guillonneau S, Bauer D, Mangan E, Graham NM, van Hoogstraten H, Lin Y et al..  (2017)  Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors..  RMD Open,  (1):  (e000416).  [PMID:28326189]
2. Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD.  (2016)  Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY..  Arthritis Res Ther,  18  (1):  (225).  [PMID:27716324]
3. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB.  (2017)  Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial..  Ann Rheum Dis,  76  (5):  (840-847).  [PMID:27856432]
4. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M et al..  (2020)  Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study..  Ann Rheum Dis,  79  (10):  (1277-1285).  [PMID:32620597]

计算器